Introduction {#S0001}
============

Prostate cancer (PCa) is one of the most common malignancy, which caused approximately 29,430 deaths in the United States in 2018.[@CIT0001] In China, the incidence of PCa is much lower than that in Western countries, but is increasing linearly every year due to unhealthy lifestyles. The growth of PCa requires androgens, which are detected by androgen receptor (AR). At early stage, PCa could be treated by radical prostatectomy, brachytherapy and radiotherapy. When PCa recurs, the androgen deprivation therapy (ADT), which inhibits the function of AR, displays good efficacy in most PCa patients. However, increased production of androgen in tumor cells, overexpression and mutation of AR, changes in coregulatory molecules and alteration of factors indirectly activating AR would invalidate ADT.[@CIT0002]--[@CIT0004] Proliferation of cancer cells was then stimulated, causing castration-resistant prostate cancer (CRPC)[@CIT0005] and finally leading to a lethal outcome.[@CIT0006]

Many studies suggest that recurrent PCa patients are neither hormone refractory nor androgen independent, but maintain a clinically reliance on the AR signaling axis.[@CIT0007]--[@CIT0009] Due to high sensitivity to the residual level of exogenous prostaglandins, the AR signaling axis is vital to the understanding of steroid synthesis signaling pathways in PCa and is a promising target pathway for the treatment of CRPC. PCa studies have focused on candidate genes based on biological pathways relevant to prostate carcinogenesis, including cytochrome P450 17A1 (CYP17A1), 17β-hydroxysteroid dehydrogenase (HSD17B) family and 5α reductase (SRD5A).[@CIT0010]--[@CIT0015] Some new drugs targeting on the AR signaling axis have been reported to successfully slowdown CRPC progression and improve survival. For example, abiraterone is an inhibitor of CYP17A1, presumably through blockade of multiple steroidogenic enzymes and antagonism of AR.[@CIT0016] Recent studies showed that abiraterone acetate and prednisone (AA/P) significantly increased overall survival (OS) in patients at castration-resistant stage.[@CIT0003],[@CIT0014],[@CIT0016]

Androsterone is synthesized by the sequential action of several enzymes, particularly CYP17A1 and heme-containing protein cytochrome b5 (CYB5A). CYB5A is a membrane-bound cytochrome that reduces methemoglobin to ferrous hemoglobin and stimulates CYP17A1 activity.[@CIT0017],[@CIT0018] Since CYP17A1 and CYB5A are directly or indirectly involved in the biosynthesis of androgen, genetic variation of these two genes may affect prostate growth, development of PCa and its sensitivity to chemical treatment.[@CIT0019]--[@CIT0021] Single nucleotide polymorphism (SNP) represents a difference in a single nucleotide in DNA sequence. It is the most common genetic variation in human. Binder et al[@CIT0022] reported that the SNP rs26486758 on CYP17A1 was associated with lower odds of experiencing a biochemical response and a shorter time to biochemical progression in CRPC patients. Besides, Wang et al[@CIT0020] revealed significant associations between rs619824, rs2486758 polymorphisms and PCa risk, as well as a significant association between rs743572 polymorphism and PCa risk in Black population but not in Caucasian or Asian populations. Salvi et al[@CIT0014] highlighted no significant associations between rs743572, rs10883783, rs17115100, rs284849 polymorphisms on CYP17A1 and clinical outcome of CRPC. However, individuals with the most common TT genotype for rs10883783 had a 3 months' longer progression-free survival (PFS) than individuals with the TA + AA genotype.[@CIT0014] Wright et al[@CIT0023] found that men with the variant A allele in rs10883783 had a 56% risk reduction in PCa-specific mortality. Obviously, studies on the relationship between prostate cancer outcomes and CYP17 gene rs743572, rs10883783 variants showed conflicting results. More investigations are still required. In CYB5A, both rs1790834 and rs1790858 were associated with rheumatoid arthritis.[@CIT0024] Furthermore, the SNP rs1790834 may help to maintain androgen levels in women.[@CIT0025] However, their relationship with PCa risk has not been reported to the best of our knowledge.

In the present study, to clarify the association between CYB5A rs1790834, rs1790858 variants and responses to AA/P, as well as to validate the association between CYP17A1 rs743572, rs10883783 variants and responses to AA/P, 58 CRPC patients were examined. Moreover, the relationship between clinical efficacy of AA/P and these SNPs were also investigated. These results may contribute more information for the clinical treatment of CRPC.

Patients and Methods {#S0002}
====================

Patients {#S0002-S2001}
--------

This study was approved by the Ethics Committee of the Fujian Provincial Hospital. As a retrospective survey, preparation of informed consent was exempted by the Ethics Committee. The study was conducted according to the principles of the Declaration of Helsinki (2013). Records and/or information of all patients were anonymized and de-identified before analyses.

From January 2015 to December 2018, approximately 80 participants diagnosed as hormone-refractory prostate cancer (HRPC) and treated with AA/P without chemotherapy or second-line treatment were collected from the Fujian Provincial Hospital and the First Hospital of Peking University. The HRPC criteria as follows: (1) Androgen deprivation with serum testosterone \<50 ng/dL; (2) Rising prostate-specific antigen (PSA) defined as three rises of PSA two weeks apart; (3) Anti-androgen withdrawal therapy for more than four weeks; (4) Progression of PSA during second-line treatment; (5) Progression of bone or soft tissue metastatic. Finally, 58 patients diagnosed as CRPC were included in the present study.

SNP Sequencing {#S0002-S2002}
--------------

Two SNPs on CYP17A1 (rs743572 and rs10883783) and two SNPs on CYB5A (rs1790834 and rs1790858) were included in the present study. Genomic DNA was isolated from whole blood using Biospin Whole Blood Genomic DNA Extraction Kit (Bioer, Hangzhou) and then stored at −20°C. Purified DNA was amplified for detection of the CYP17A1 and CYB5A variants using the TaqMan real-time quantitative polymerase chain reaction (RT-qPCR) assay.[@CIT0026] Primer sequences and TaqMan probes are shown in [Table 1](#T0001){ref-type="table"}. For each 25 μL of PCR reaction, 5 μL extracted DNA was used. The reaction was initially carried out at 95 °C for 10 min, followed by 40 cycles of denaturation at 94 °C for 30 s, annealing at 42 °C for 90 s, and extension at 72 °C for 30 s, with a final extension at 72 °C for 5 min. All DNA samples were analyzed in duplicate using a TaqMan PCR Master Mix on a 7500 real-time PCR cycler according to the manufacturer's instructions.Table 1Primer Sequences and TaqMan Probes of rs743572, rs10883783, rs1790834 and rs1790858GenesPrimer SequencesTaqMan Probes*rs743572*Forward 5ʹ-TTGGGCCAAAACAAATAAGC-3ʹ\
Reverse 5ʹ-GGGCTCCAGGAGAATCTTTC-3'5ʹ-CGGTGGAGTAGAAGAG-3'*rs10883783*Forward 5ʹ-CTATGGCAGGATGAGGGTGT-3ʹ\
Reverse 5ʹ-TGAGTTTGCTGTGGACAAGG-3'5ʹ-TGGAGCCAAGAGTTT-3'*rs1790834*Forward 5ʹ-ATACGGACTGACCCCATCTG-3ʹ\
Reverse 5ʹ-CCAGTCCACCAGGACATTCT-3'5ʹ-TGGAGCCAAGAGTTT-3'*rs1790858*Forward 5ʹ-CGAACTGCTGGACTCAAG-3ʹ\
Reserve 5ʹ-GATTATCTTCTTGGCTCTGTAG-3'5ʹ-GAGGGGACCACGCGAGAGA-3'

Clinical Data {#S0002-S2003}
-------------

Treatment consisted of 28-day cycles of 1000 mg of abiraterone acetate daily on an empty stomach with 5 mg of prednisone twice per day. Treatment continued until there was evidence of disease progression and/or unacceptable toxicity. Before commencement of treatment, blood samples were collected from all patients to measure the level of PSA, and all patients underwent a computed tomography (CT) scan of the chest and abdomen. Patients were evaluated monthly to check the change of PSA level and to monitor any hepatic and renal toxicity. CT scan was performed every 3 months during treatment with abiraterone. Disease progression was defined according to the Prostate Cancer Working Group 2 (PCWG2) criteria.[@CIT0027] Compared with the PSA level before treatment, a 50% decline of PSA level, which could be repeatedly confirmed after at least three weeks, was considered as non-progression. Progression was defined as the increase in PSA. After therapied by AA/P, the data of PSA level, testosterone level, age, tumor node metastasis (TNM) stages, Gleason score and Eastern Cooperative Oncology Group (ECOG) for each patient were recorded.

Statistical Analysis {#S0002-S2004}
--------------------

Tests for Hardy--Weinberg equilibrium were performed for each SNP. Fisher's exact test and Chi-square test were used to compare biochemical responses to AA/P between various SNP groups. PFS was defined as the time from the starting date of abiraterone treatment to the first observation of progression, relapse or death (whichever came first). OS was defined as the time from the starting date of abiraterone treatment to the date of death resulted from any cause. The Kaplan--Meier method was used to estimate PFS and OS. The Log-rank test was carried out to compare the PFS and OS curves between different genotypes. Logistic regression was used for association analyses. Odds ratios (OR) and 95% confidential intervals (CI) were calculated. Cox proportional hazards regression was used to assess the association between genetic variation and time to biochemical progression. All statistical tests were two-sided, and *P* \< 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 23.0.

Results {#S0003}
=======

The clinical and pathological characteristics of the 58 patients included in the present study are shown in [Table 2](#T0002){ref-type="table"}. At the time of initial PCa diagnosis, the median age, PSA level and testosterone level of patients were 69 years, 4.75 ng/mL and 0.95 nmol/L, respectively. Forty-eight patients (83%) had Gleason score of ≥8.Table 2Clinical Characteristics of the 58 Patients Involved in the Present Study. Demographics Were the Values at the Time of Initial DiagnosisIndicesValuesDemographics Median age (years)69 (50--82) Median prostate-specific antigen (ng/mL)4.75 (1--67.8) Median testosterone level (nmol/L)0.95 (0.3--7)Stage T1-T2b0 (0%) T2c1 (2%) T3+57 (98%) N+27 (47%) M+58 (100%)Gleason Grade 5--60 (0%) 710 (17%) 8--1048 (83%) Chemotherapy25 (43%)ECOG Score 0--157 (98%) 21 (2%)[^1]

All studied SNP polymorphisms were in Hard-Weinberg equilibrium (HWE). PSA level decreased for 50% was defined as effective PSA response. Statistical analyses showed a significant association between rs1790834 and PSA response (AA vs GG, *P* = 0.02; AG + AA vs GG, *P* = 0.047), but no significant association between rs743572, rs10883783, rs1790858 and PSA response ([Tables 3](#T0003){ref-type="table"} and [4](#T0004){ref-type="table"}).Table 3Association of CYP17A1 and CYB5A Gene Polymorphisms with PSA Response. PSA Response Was Defined as 50% Reduction of PSA Level After Treatment with AA/PGenotypeCase Number (%)*P* valueOR (95% Confidential Interval)rs1790834 (G\>A) GG^a^27 (46.6)1.000 (reference) AG26 (44.8)0.110-- AA5 (8.6)0.020^b^-- AG+AA31 (53.4)0.047--rs1790858 (C\>T) CC^a^25 (43.1)1.000 (reference) CT27 (46.6)1.0001.091 (0.199--5.981) TT6 (10.3)1.000^b^-- CT+TT33 (56.9)1.0001.364 (0.251--7.407)rs10883783 (T\>A) TT^a^2 (3.4)1.000 (reference) AT27 (46.6)0.200^b^0.080 (0.004--1.818) AA29 (50)0.245^b^0.115 (0.006--2.361) AT+AA56 (96.6)0.198^b^10.2 (0.55--189.125)rs743572 (A\>G/A\>T) AA^a^14 (24.1)1.000 (reference) AG/AT33 (56.9)1.0000.558 (0.057--5.490) GG/TT11 (19.0)1.000^b^0.769 (0.043--13.866) AG+GG/AT+TT44 (75.9)1.0000.600 (0.064--5.619)[^2][^3] Table 4Logistic Regression Analyses Between rs1790834 Variants and PSA ResponseModelrs1790834rs1790858rs10883783rs743572UnadjustedOR (NA), *P* = 0.025OR (NA), *P* = 0.7483.54 (0.051--247.277), *P* = 0.2760.688 (0.047--10.103), *P* = 0.799Age-adjustedOR (NA), *P* = 0.025OR (NA), *P* = 0.7554.29 (0.069--266.691), *P* = 0.2880.688 (0.047--10.093), *P* = 0.791TNM-adjustedOR (NA), *P* = 0.020OR (NA), *P* (NA)OR (NA), *P* = 0.430OR (NA), *P* (NA)[^4]

Based on the data of all CRPC patients, treatment with AA/P revealed the median PFS of 12 months (95% CI: 10.794--13.206) and the median OS of 28 months (95% CI: 24.526--31.474) ([Figure 1](#F0001){ref-type="fig"}). For rs1790834, significant differences in either PFS or OS were detected between patients with GG and AG + AA (*P* \< 0.001). The PFS of patients with GG variant (14 months) was 4 months longer than those with AG+AA genotype (10 months) ([Figure 2](#F0002){ref-type="fig"}).Figure 1Kaplan--Meier curves of progression-free survival (**A**) and overall survival (**B**) for all 58 patients.Figure 2Kaplan--Meier curves of progression-free survival (**A**) and overall survival (**B**) for patients with different CYP17A1 rs1790834 genotypes.

The results of Cox proportional hazards analyses for PFS and OS are shown in [Table 5](#T0005){ref-type="table"}. Cox regression analysis with adjustment for age, Gleason score and tumor stage at diagnosis showed that rs1790834 variation significantly affected PFS and OS of CRPC patients. The hazard ratios of AG genotype and AA genotype were greatly higher than those of GG genotype for both PFS and OS.Table 5Cox Proportional Hazards Model of Biochemical Progression for CRPC PatientsGenes rs1790834Progression-Free SurvivalOverall SurvivalGG^a^HR 1.000 (reference), *P* \<0.001HR 1.000 (reference), *P* \< 0.001AGHR 2.752 (1.415--5.354), *P* = 0.003HR 9.248 (2.253--37.959), *P* = 0.002AAHR 10.624 (3.012--37.47), *P* \<0.001HR 42.492 (7.074--255.253), *P* \< 0.001rs1790858CC^a^HR 1.000 (reference), *P* = 0.883HR 1.000 (reference), *P* =0.393CTHR 1.132 (0.570--2.250), *P* = 0.723HR 0.730 (0.240--2.224), *P* = 0.580TTHR 0.893 (0.309--2.576), *P* = 0.834HR 2.099 (0.543--8.111), *P* = 0.282rs10883783TT^a^HR 1.000 (reference), *P* = 0.719HR 1.000 (reference), *P* = 0.892ATHR 0.576 (0.108--3.081), *P* = 0.519HR 1.581 (0.131--19.027), *P* = 0.718AAHR 0.715 (0.137--3.717), *P* = 0.690HR 1.774 (0.157--20.037), *P* = 0.643rs743572AA^a^HR 1.000 (reference), *P* = 0.917HR 1.000 (reference), *P* = 0.366AG/ATHR 1.025 (0.451--2.326), *P* = 0.954HR 0.897 (0.277--2.912), *P* = 0.857GG/TTHR 1.222 (0.408--3.657), *P* = 0.721HR 2.373 (0.466--12.081), *P* = 0.298[^5][^6]

Discussion {#S0004}
==========

Endogenous hormones, especially androgens, are required for essential prostate functions, and affect the proliferation and differentiation of luminal epithelia.[@CIT0012] Since endogenous factors affecting the functional genome may differ among different populations, it is important to define the polymorphic spectrum of genes that are implicated in cancer causation. The biosynthesis of androgens depends on two key enzymes, 17α-hydroxylase and 17.20-lyase. Both of them link to CYP17A,[@CIT0028] and 17.20-lyase activity requires additional participation of P450 oxidoreductase and CYB5A.[@CIT0029] In addition, CYB5A is also involved in a number of other processes such as drug metabolism and fatty acid desaturation.[@CIT0030] Thus, CYP17A and CYB5A are greatly important to androgen synthesis and may influence prostatic carcinogenesis and its sensitivity to chemotherapy.

In previous studies, the rs743572 and rs10883783 polymorphism of CPY17A1 showed no significant association with PCa risk.[@CIT0031]--[@CIT0034] A meta-analysis between 2404 PCa patients and 2755 health persons concluded that the rs743572 polymorphism was unlikely to alter PCa risk.[@CIT0035] In the present study, rs10883783 and rs743572 on CYP17A1 did not show significant association with PSA response, suggesting that mutation on these two sites might not contribute to efficacy and AA/P treatment in Chinese patients. These results were consistent with the results provided by Wang et al,[@CIT0020] Salvi et al,[@CIT0014] Han et al[@CIT0012] and Severi et al,[@CIT0031] but conflicted with the results from African-American and Japanese men.[@CIT0023],[@CIT0036],[@CIT0037] Salvi et al[@CIT0014] revealed that patients with TT genotype on rs10883783 showed better survival than TA + AA genotype, but Wright et al[@CIT0023] found that the variant A allele had a lower risk of PCa-specific mortality. In the present study, our data cannot support or deny these two conclusions, due to insufficient sample size. Only two patients had TT variant on rs10883783 in the present study. More samples are still required to test this hypothesis on Chinese population in future.

Compared with CYP17A1, association between efficacy of AA/P treatment and SNPs on CYB5A was less investigated. In the present study, two SNPs (rs1790858 and rs1790834) were investigated. SNPs rs1790858 showed no significant association with PSA response. However, rs1790834 was significantly correlated with PSA response. More importantly, the variant AG+AA showed significantly lower PFS and OS than GG, respectively. These results indicated that patients with AG + AA might be less effective to AA/P treatment than GG, which could be useful for selection of therapeutic plan. To the best of our knowledges, this is the first report for the relationship between rs1790834 and efficacy of AA/P treatment in PCa patients.

In humans, CYP17A1 catalyzes the 17α-hydroxylase and 17.20-lyase reactions to convert pregnenolone to 17α-hydroxypregnenolone and dehydroepiandrosterone (DHEA), and also catalyzes the 17.20 lyase reaction to produce androstenone.[@CIT0038],[@CIT0039] DHEA and androstenone are the precursors of androgen and testosterone.[@CIT0040] Meanwhile, CYB5A promotes the 17.20-lyase reaction by CYP17A1. Peacock et al[@CIT0041] identified a rare polymorphism on the pig CYB5A gene just upstream of the translational start site, which decreased levels of CYB5A and synthesis of androstenone. Similarly, the SNP rs1790834 is localized to the intron 1 of the CYB5A gene in humans. Genotype dependent gene expression in synovial fibroblasts, a cell type potentially responsible for androgen biosynthesis in the joint, showed an association between the rare allele of rs1790834 and increased CYB5A expression,[@CIT0024],[@CIT0025] which then should promote the biosynthesis of androgen. A high level of androgen would negatively affect the efficacy of ADT and then increase the risk of CRPC.

Associations between four SNPs and efficacy of ADT were analyzed in the present study. The results showed that the SNP rs1790834 might be a promising biomarker for selection of the best treatment method for CRPC patients. However, the present study only investigated 58 patients and all the patients were from the mainland of China. Investigations on more patients are still required to test the conclusions in different populations. Moreover, the present study demonstrated that CYB5A was an important gene for CRPC patients. The pharmacokinetics and pharmacodynamics of abiraterone on patients with different CYB5A genotypes should be further investigated.

Conclusion {#S0005}
==========

This study found that the SNP rs1790834 is associated with the efficacy of AA/P in CRPC patients and decreases the sensitivity of patients to ADT. No associations were found between the SNPs rs743572, rs10883783, 1790858 and PSA response. There is a promising approach of primary genotyping to select the best treatment method in prostate cancer patients.
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[^1]: **Abbreviation:** ECOG, Eastern Cooperative Oncology Group.

[^2]: **Notes:** ^a^Reference group. ^b^Fisher's exact test.

[^3]: **Abbreviation:** PSA, prostate-specific antigen.

[^4]: **Abbreviations:** PSA, prostate-specific antigen; OR, odds ratio; NA, not available; TNM, tumor node metastasis.

[^5]: **Note:** ^a^Reference group.

[^6]: **Abbreviations:** CRPC, castration-resistant prostate cancer, HR, hazard ratio.
